National Asset Management Inc. Acquires Shares of 46,876 Heron Therapeutics, Inc. (HRTX)

National Asset Management Inc. acquired a new position in Heron Therapeutics, Inc. (NASDAQ:HRTX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 46,876 shares of the biotechnology company’s stock, valued at approximately $650,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC purchased a new position in Heron Therapeutics during the second quarter valued at approximately $78,134,000. Tang Capital Management LLC increased its holdings in Heron Therapeutics by 39.7% during the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock valued at $129,824,000 after buying an additional 2,457,716 shares during the period. FMR LLC increased its holdings in Heron Therapeutics by 36.7% during the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after buying an additional 2,158,041 shares during the period. Janus Capital Management LLC increased its holdings in Heron Therapeutics by 20.2% during the first quarter. Janus Capital Management LLC now owns 5,501,755 shares of the biotechnology company’s stock valued at $82,524,000 after buying an additional 925,948 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Heron Therapeutics by 40.2% during the first quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock valued at $28,127,000 after buying an additional 537,563 shares during the period.

Several equities analysts recently issued reports on HRTX shares. Zacks Investment Research raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Wednesday, July 12th. Aegis reissued a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Heron Therapeutics in a report on Monday, June 26th. ValuEngine raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $28.50.

TRADEMARK VIOLATION NOTICE: This story was reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/10/13/national-asset-management-inc-acquires-shares-of-46876-heron-therapeutics-inc-hrtx.html.

Heron Therapeutics, Inc. (NASDAQ:HRTX) traded down 2.742% during midday trading on Friday, hitting $15.075. 397,647 shares of the stock traded hands. Heron Therapeutics, Inc. has a one year low of $12.21 and a one year high of $20.85. The company has a 50-day moving average price of $16.01 and a 200 day moving average price of $15.18. The stock’s market cap is $816.13 million.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. Equities research analysts anticipate that Heron Therapeutics, Inc. will post ($3.51) earnings per share for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply